AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1941390 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 178
Study 1941390 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Number of subjects: 178
Study 7076005 — intervention group
Group type: EXPERIMENTAL
Intervention: Bedtime chenic acid plus low cholesterol diet
Number of subjects: 10
Study 7076005 — intervention group
Group type: EXPERIMENTAL
Intervention: Bedtime chenic acid
Number of subjects: 10
Study 7076005 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional regimen of mealtime chenic acid
Number of subjects: 10
Study 7076005 — intervention group
Group type: EXPERIMENTAL
Intervention: All regimens
Number of subjects: 10
Study 29721503 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency current (RFC)
Number of subjects: 89
Study 29721503 — intervention group
Group type: COMPARATOR
Intervention: Cryoballoon
Number of subjects: 89
Study 27514768 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc sulfate syrup plus routine treatment of UTI
Number of subjects: 200
Study 27514768 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment protocol for UTI
Number of subjects: 200
Study 24933717 — intervention group
Group type: EXPERIMENTAL
Intervention: Oculomotor training (OMT)
Number of subjects: 12
Study 24933717 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P) training
Number of subjects: 12
Study 21972797 — intervention group
Group type: EXPERIMENTAL
Intervention: Perception/cognition
Number of subjects: 0
Study 21972797 — intervention group
Group type: EXPERIMENTAL
Intervention: Language-specific semantics
Number of subjects: 0
Study 21972797 — intervention group
Group type: EXPERIMENTAL
Intervention: English language
Number of subjects: 0
Study 21972797 — intervention group
Group type: EXPERIMENTAL
Intervention: Korean language
Number of subjects: 0
Study 20032273 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with greater self-esteem and presented with an alternative positive social identity (college students)
Number of subjects: 0
Study 20032273 — intervention group
Group type: COMPARATOR
Intervention: Women lower in self-esteem
Number of subjects: 0
Study 18533934 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfacarcidol (vitamin D)
Number of subjects: 20
Study 18533934 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfacarcidol (vitamin D) + Risedronate (bisphosphonate)
Number of subjects: 20
Study 18533934 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate (bisphosphonate)
Number of subjects: 20
Study 15777446 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E
Number of subjects: 278
Study 15777446 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 278
Study 12439072 — intervention group
Group type: EXPERIMENTAL
Intervention: Group‐mediated cognitive‐behavioral intervention (GMCB)
Number of subjects: 147
Study 12439072 — intervention group
Group type: COMPARATOR
Intervention: Traditional cardiac rehabilitation (CRP)
Number of subjects: 147
Study 9715775 — intervention group
Group type: EXPERIMENTAL
Intervention: Active compression-decompression CPR (ACD-B)
Number of subjects: 14
Study 9715775 — intervention group
Group type: EXPERIMENTAL
Intervention: Active compression-decompression CPR (ACD-S)
Number of subjects: 14
Study 9715775 — intervention group
Group type: COMPARATOR
Intervention: Standard CPR
Number of subjects: 14
Study 7707120 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN/5‐FU (9 MIU interferon alfa-2a subcutaneously three times per week, 5‐FU 750 mg/m2/d by continuous intravenous infusion on days 1 to 5, then weekly i.v. bolus)
Number of subjects: 496
Study 7707120 — intervention group
Group type: COMPARATOR
Intervention: LV/5‐FU (200 mg/m2/d leucovorin by i.v. infusion plus 5‐FU 370 mg/m2/d by i.v. bolus on days 1 to 5, repeated every 4 weeks)
Number of subjects: 496
Study 2533034 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII)
Number of subjects: 30
Study 2533034 — intervention group
Group type: COMPARATOR
Intervention: Conventional injection therapy
Number of subjects: 30
Study 335041 — intervention group
Group type: EXPERIMENTAL
Intervention: Povidone iodine
Number of subjects: 0
Study 335041 — intervention group
Group type: COMPARATOR
Intervention: Placebo preparation
Number of subjects: 0
Study 30940341 — intervention group
Group type: EXPERIMENTAL
Intervention: Vorvida intervention
Number of subjects: 608
Study 30940341 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 608
Study 28472101 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estradiol (E2) treatment for 1 week
Number of subjects: 35
Study 28472101 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL) treatment for 1 week
Number of subjects: 35
Study 28472101 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estradiol (E2) treatment
Number of subjects: 35
Study 25832111 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication
Number of subjects: 42
Study 25832111 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 23808527 — intervention group
Group type: EXPERIMENTAL
Intervention: Financial incentive (exit exam)
Number of subjects: 121
Study 23808527 — intervention group
Group type: COMPARATOR
Intervention: Control (book voucher raffle)
Number of subjects: 121
Study 23808527 — intervention group
Group type: EXPERIMENTAL
Intervention: Financial incentive
Number of subjects: 121
Study 23808527 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 121
Study 21788837 — intervention group
Group type: EXPERIMENTAL
Intervention: Intense pulsed light treatment (two times per week for 4 weeks using a Harmony Laser)
Number of subjects: 18
Study 21788837 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment on the contralateral side)
Number of subjects: 18
Study 21788837 — intervention group
Group type: EXPERIMENTAL
Intervention: Intense pulsed light treatment
Number of subjects: 18
Study 19519240 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV prevalence
Number of subjects: 156
Study 19519240 — intervention group
Group type: EXPERIMENTAL
Intervention: Other sexually transmitted diseases prevalence
Number of subjects: 156
Study 19519240 — intervention group
Group type: EXPERIMENTAL
Intervention: Reported sexual behavior
Number of subjects: 156
Study 19519240 — intervention group
Group type: EXPERIMENTAL
Intervention: Recent anal intercourse partners
Number of subjects: 156
Study 19519240 — intervention group
Group type: EXPERIMENTAL
Intervention: Unprotected anal intercourse
Number of subjects: 156
Study 19519240 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk predictors
Number of subjects: 156
Study 17466464 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-syringe paraphernalia-sharing (NSPS)
Number of subjects: 0
Study 17466464 — intervention group
Group type: EXPERIMENTAL
Intervention: Syringe-mediated drug-splitting (SMDS)
Number of subjects: 0
Study 14999204 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-based educational intervention
Number of subjects: 756
Study 14999204 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 756
Study 11707555 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy-restricted diet of 1200 to 1500 kcal/d (Group A)
Number of subjects: 100
Study 11707555 — intervention group
Group type: EXPERIMENTAL
Intervention: Isocaloric diet with nutrient-fortified liquid meal replacements (Group B)
Number of subjects: 100
Study 9208965 — intervention group
Group type: EXPERIMENTAL
Intervention: Impra graft
Number of subjects: 117
Study 9208965 — intervention group
Group type: COMPARATOR
Intervention: Goretex graft
Number of subjects: 117
Study 7783570 — intervention group
Group type: EXPERIMENTAL
Intervention: ECGs with computer-generated reports
Number of subjects: 40
Study 7783570 — intervention group
Group type: COMPARATOR
Intervention: ECGs without reports
Number of subjects: 40
Study 1982764 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine (150 mg) alone
Number of subjects: 18
Study 1982764 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine (150 mg) with piroxicam (40 mg)
Number of subjects: 18
Study 1982764 — intervention group
Group type: COMPARATOR
Intervention: Piroxicam (20 mg) with placebo
Number of subjects: 18
Study 1982764 — intervention group
Group type: EXPERIMENTAL
Intervention: Piroxicam (20 mg) with ranitidine (150 mg)
Number of subjects: 18
Study 356867 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (50 mg)
Number of subjects: 21
Study 356867 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (40 mg)
Number of subjects: 21
Study 356867 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 30650232 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall Compliance in TAIL treatment
Number of subjects: 207
Study 30650232 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific Compliance in TAIL treatment
Number of subjects: 207
Study 30650232 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific Compliance with stress and insomnia components
Number of subjects: 207
Study 28286047 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide (ACTZ) 500 mg
Number of subjects: 47
Study 28286047 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 25039889 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren (150 mg) added to valsartan (80 mg)
Number of subjects: 28
Study 25039889 — intervention group
Group type: COMPARATOR
Intervention: Valsartan (80 mg) alone
Number of subjects: 28
Study 22702891 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurologists' assessment of depression
Number of subjects: 104
Study 22702891 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurologists' assessment of cognitive impairment
Number of subjects: 104
Study 22702891 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients' self-assessment of depression
Number of subjects: 104
Study 22702891 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients' self-assessment of cognitive impairment
Number of subjects: 104
Study 20350038 — intervention group
Group type: EXPERIMENTAL
Intervention: Group cognitive-behavioral (CB) intervention
Number of subjects: 0
Study 20350038 — intervention group
Group type: EXPERIMENTAL
Intervention: Group supportive expressive intervention
Number of subjects: 0
Study 20350038 — intervention group
Group type: EXPERIMENTAL
Intervention: CB bibliotherapy
Number of subjects: 0
Study 20350038 — intervention group
Group type: COMPARATOR
Intervention: Assessment-only control condition
Number of subjects: 0
Study 18538406 — intervention group
Group type: EXPERIMENTAL
Intervention: Brinzolamide 1%/timolol 0.5%
Number of subjects: 523
Study 18538406 — intervention group
Group type: COMPARATOR
Intervention: Brinzolamide 1%
Number of subjects: 523
Study 18538406 — intervention group
Group type: COMPARATOR
Intervention: Timolol 0.5%
Number of subjects: 523
Study 16275826 — intervention group
Group type: EXPERIMENTAL
Intervention: Surrogate consent for biomedical research in minimal risk studies
Number of subjects: 229
Study 16275826 — intervention group
Group type: EXPERIMENTAL
Intervention: Surrogate consent for randomized clinical trials of new medications
Number of subjects: 229
Study 16275826 — intervention group
Group type: EXPERIMENTAL
Intervention: Surrogate consent for more invasive studies
Number of subjects: 229
Study 16275826 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision-making for a loved one
Number of subjects: 229
Study 16275826 — intervention group
Group type: EXPERIMENTAL
Intervention: General attitude toward biomedical research and scenario-specific risk perception
Number of subjects: 229
Study 16275826 — intervention group
Group type: EXPERIMENTAL
Intervention: Demographic and personal history variables
Number of subjects: 229
Study 14605518 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week exercise training intervention
Number of subjects: 23
Study 14605518 — intervention group
Group type: COMPARATOR
Intervention: Standard pharmacologic therapy
Number of subjects: 23
Study 10394887 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibitor (group I, 6 patients)
Number of subjects: 12
Study 10394887 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta blocker (group II, 6 patients)
Number of subjects: 12
Study 8523341 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone 20 mg/day
Number of subjects: 30
Study 8523341 — intervention group
Group type: COMPARATOR
Intervention: Deflazacort 24 mg/day
Number of subjects: 30
Study 2334306 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonverbal auditory stimuli
Number of subjects: 14
Study 2334306 — intervention group
Group type: COMPARATOR
Intervention: Binaural auditory verbal stimuli
Number of subjects: 14
Study 2334306 — intervention group
Group type: COMPARATOR
Intervention: Tactile unilateral and bilateral stimuli
Number of subjects: 14
Study 2334306 — intervention group
Group type: COMPARATOR
Intervention: No stimulation at all
Number of subjects: 14
Study 395954 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicergoline
Number of subjects: 60
Study 395954 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 31186202 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard analgesia plus Battlefield Auricular Acupuncture (BFA)
Number of subjects: 70
Study 31186202 — intervention group
Group type: COMPARATOR
Intervention: Standard analgesia
Number of subjects: 70
Study 28138865 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensorial training of the posterior thigh in addition to neurodevelopmental treatment
Number of subjects: 26
Study 28138865 — intervention group
Group type: COMPARATOR
Intervention: Neurodevelopmental treatment only (control group)
Number of subjects: 26
Study 26164864 — intervention group
Group type: EXPERIMENTAL
Intervention: Urapidil
Number of subjects: 72
Study 26164864 — intervention group
Group type: COMPARATOR
Intervention: Nitroglycerin (NG)
Number of subjects: 72
Study 23657083 — intervention group
Group type: EXPERIMENTAL
Intervention: DC/PANVAC
Number of subjects: 74
Study 23657083 — intervention group
Group type: COMPARATOR
Intervention: PANVAC with GM-CSF
Number of subjects: 74
Study 23657083 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccinated patients
Number of subjects: 74
Study 21680669 — intervention group
Group type: EXPERIMENTAL
Intervention: Information on how women may benefit from men's HPV vaccination
Number of subjects: 150
Study 21680669 — intervention group
Group type: EXPERIMENTAL
Intervention: Information on preventing genital warts
Number of subjects: 150
Study 21680669 — intervention group
Group type: EXPERIMENTAL
Intervention: Information on preventing head and neck cancers
Number of subjects: 150
Study 21680669 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific information provided)
Number of subjects: 150
Study 19628934 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin treatment in the UK‐TIA Trial
Number of subjects: 0
Study 19628934 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy in the European Carotid Surgery Trial (ECST)
Number of subjects: 0
Study 17908579 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric gaseous cryotherapy (2min at 75 bar and -78 degrees C)
Number of subjects: 12
Study 17908579 — intervention group
Group type: COMPARATOR
Intervention: Ice bag (15min)
Number of subjects: 12
Study 15529649 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycerin formulation of ototopical 0.3% ciprofloxacin
Number of subjects: 33
Study 15529649 — intervention group
Group type: COMPARATOR
Intervention: Conventional aqueous formulation of ciprofloxacin
Number of subjects: 33
Study 15529649 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 33
Study 11211149 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon‐α (IFN‐α)
Number of subjects: 9
Study 11211149 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon‐α (IFN‐α) with anthracycline‐containing induction chemotherapy
Number of subjects: 9
Study 11211149 — intervention group
Group type: COMPARATOR
Intervention: Control group (no IFN‐α)
Number of subjects: 9
Study 9012900 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (NO) at a low dose of 10 ppm
Number of subjects: 22
Study 9012900 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic inhalation of nitric oxide (NO)
Number of subjects: 22
Study 10146734 — intervention group
Group type: EXPERIMENTAL
Intervention: Clear Horizons and two counselor calls
Number of subjects: 2000
Study 10146734 — intervention group
Group type: EXPERIMENTAL
Intervention: Clear Horizons alone
Number of subjects: 2000
Study 10146734 — intervention group
Group type: COMPARATOR
Intervention: Control guide (Clearing the Air)
Number of subjects: 2000
Study 10146734 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored interventions (Clear Horizons)
Number of subjects: 2000
Study 3580158 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin and fluorouracil as neoadjuvant chemotherapy followed by standard treatment.
Number of subjects: 60
Study 3580158 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (preoperative irradiation followed by radical excision or irradiation alone).
Number of subjects: 60
Study 3580158 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (adjuvant chemotherapy followed by standard treatment).
Number of subjects: 60
Study 29650764 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Number of subjects: 758
Study 29650764 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline PRA
Number of subjects: 758
Study 29650764 — intervention group
Group type: EXPERIMENTAL
Intervention: TXNDC11 expression
Number of subjects: 758
Study 29650764 — intervention group
Group type: EXPERIMENTAL
Intervention: Proxy SNP rs1802409
Number of subjects: 758
Study 27391833 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat grafting (mean volume of 4.8 cc per foot)
Number of subjects: 25
Study 27391833 — intervention group
Group type: COMPARATOR
Intervention: Conservative management
Number of subjects: 25
Study 25007905 — intervention group
Group type: EXPERIMENTAL
Intervention: Venotrain ulcertec® (VU) compression stocking
Number of subjects: 60
Study 25007905 — intervention group
Group type: EXPERIMENTAL
Intervention: Venotrain micro® (VM) compression stocking
Number of subjects: 60
Study 25007905 — intervention group
Group type: COMPARATOR
Intervention: Control (no compression)
Number of subjects: 60
Study 24322122 — intervention group
Group type: EXPERIMENTAL
Intervention: Correction of defocus fluctuations
Number of subjects: 4
Study 24322122 — intervention group
Group type: COMPARATOR
Intervention: All aberrations except defocus were corrected
Number of subjects: 4
Study 24322122 — intervention group
Group type: COMPARATOR
Intervention: Uncorrected aberrations
Number of subjects: 4
Study 20467269 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan
Number of subjects: 3071
Study 18383418 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 315
Study 18383418 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 315
Study 16632233 — intervention group
Group type: EXPERIMENTAL
Intervention: 3x daily insulin lispro
Number of subjects: 159
Study 16632233 — intervention group
Group type: EXPERIMENTAL
Intervention: 3x daily lispro mid mixture (MidMix; 50% lispro, 50% protaminated lispro)
Number of subjects: 159
Study 16632233 — intervention group
Group type: COMPARATOR
Intervention: 1x daily insulin glargine
Number of subjects: 159
Study 16632233 — intervention group
Group type: EXPERIMENTAL
Intervention: 3x daily lispro mid mixture (MidMix)
Number of subjects: 159
Study 16632233 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 159
Study 14653833 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole
Number of subjects: 19
Study 14653833 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 10759875 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin
Number of subjects: 12
Study 10759875 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 8833708 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperhydration (HH) with fluid intake of 4.6 ± 0.2.day(‐1)
Number of subjects: 8
Study 8833708 — intervention group
Group type: COMPARATOR
Intervention: Voluntary hydration (VH) with fluid intake of 2.7 ± 0.2.day(‐1)
Number of subjects: 8
Study 8833708 — intervention group
Group type: EXPERIMENTAL
Intervention: Both hydration conditions (HH and VH)
Number of subjects: 8
Study 1385036 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 674
Study 1385036 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 674
Study 3881633 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency lung ventilation
Number of subjects: 0
Study 3881633 — intervention group
Group type: COMPARATOR
Intervention: Conventional mechanical lung ventilation
Number of subjects: 0
Study 30789801 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-lipoic acid (ALA) 1200 mg/day for 8 weeks
Number of subjects: 70
Study 30789801 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 29509867 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid medications (immediate-release morphine, oxycodone, or hydrocodone/acetaminophen)
Number of subjects: 240
Study 29509867 — intervention group
Group type: COMPARATOR
Intervention: Nonopioid medications (acetaminophen or NSAIDs)
Number of subjects: 240
Study 29509867 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid medications
Number of subjects: 240
Study 29509867 — intervention group
Group type: COMPARATOR
Intervention: Nonopioid medications
Number of subjects: 240
Study 27338193 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin plus paclitaxel doublet chemotherapy
Number of subjects: 451
Study 27338193 — intervention group
Group type: COMPARATOR
Intervention: Monotherapy (vinorelbine or gemcitabine)
Number of subjects: 451
Study 24937018 — intervention group
Group type: EXPERIMENTAL
Intervention: Iyengar yoga (twice weekly)
Number of subjects: 0
Study 24937018 — intervention group
Group type: COMPARATOR
Intervention: Health and wellness classes (twice weekly)
Number of subjects: 0
Study 22716999 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg escitalopram daily for 7 days
Number of subjects: 42
Study 22716999 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 19130460 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin
Number of subjects: 20
Study 19130460 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 17684066 — intervention group
Group type: EXPERIMENTAL
Intervention: Biventricular (BiV) pacing
Number of subjects: 18